XML 71 R57.htm IDEA: XBRL DOCUMENT v3.20.4
Fair value of financial instruments and investments - Schedule of financial assets and liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Aug. 23, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Marketable securities $ 894,838 $ 398,535  
Deferred consideration payable 0    
Contingent consideration payable 240,400 356,300  
Level 2      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
ClearPoint convertible debt security 29,300    
Level 3      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
ClearPoint convertible debt security 0    
Contingent consideration payable- net sales milestones and royalties 101,200    
Recurring basis | Total      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Marketable securities 894,838 398,535  
Equity investment in ClearPoint 20,503 6,194  
ClearPoint convertible debt security 29,252    
Stock appreciation rights liability   3,186  
Deferred consideration payable   40,000  
Contingent consideration payable 139,200 290,500  
Contingent consideration payable- net sales milestones and royalties 101,200 65,800  
Recurring basis | Level 1      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Marketable securities 0 0  
Equity investment in ClearPoint 20,503 6,194  
ClearPoint convertible debt security 0    
Stock appreciation rights liability   0  
Deferred consideration payable   0  
Contingent consideration payable 0 0  
Contingent consideration payable- net sales milestones and royalties 0 0  
Recurring basis | Level 2      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Marketable securities 894,838 398,535  
Equity investment in ClearPoint 0 0  
ClearPoint convertible debt security 29,252    
Stock appreciation rights liability   0  
Deferred consideration payable   40,000  
Contingent consideration payable 0 0  
Contingent consideration payable- net sales milestones and royalties 0 0  
Recurring basis | Level 3      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Marketable securities 0 0  
Equity investment in ClearPoint 0 0  
Stock appreciation rights liability   3,186  
Deferred consideration payable   0  
Contingent consideration payable $ 139,200 290,500  
Contingent consideration payable- net sales milestones and royalties   $ 65,800  
Agilis      
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]      
Deferred consideration payable     $ 38,100